A detailed history of Royal Bank Of Canada transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,871 shares of TBPH stock, worth $24,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,871
Previous 17,015 83.13%
Holding current value
$24,346
Previous $191,000 86.91%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$8.22 - $11.59 $116,263 - $163,928
-14,144 Reduced 83.13%
2,871 $25,000
Q4 2023

Feb 14, 2024

BUY
$8.58 - $11.4 $63,903 - $84,907
7,448 Added 77.85%
17,015 $191,000
Q3 2023

Nov 14, 2023

BUY
$8.38 - $10.44 $25,433 - $31,685
3,035 Added 46.46%
9,567 $82,000
Q2 2023

Aug 14, 2023

BUY
$10.16 - $11.92 $16,753 - $19,656
1,649 Added 33.77%
6,532 $67,000
Q1 2023

May 15, 2023

SELL
$9.87 - $11.44 $59,910 - $69,440
-6,070 Reduced 55.42%
4,883 $52,000
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $41,909 - $49,249
4,343 Added 65.7%
10,953 $122,000
Q3 2022

Nov 14, 2022

BUY
$8.39 - $10.22 $51,581 - $62,832
6,148 Added 1330.74%
6,610 $67,000
Q2 2022

Aug 15, 2022

SELL
$8.41 - $10.34 $105,713 - $129,973
-12,570 Reduced 96.45%
462 $4,000
Q1 2022

May 16, 2022

SELL
$8.33 - $12.96 $98,327 - $152,979
-11,804 Reduced 47.53%
13,032 $124,000
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $27,624 - $41,139
3,723 Added 17.63%
24,836 $275,000
Q3 2021

Nov 15, 2021

SELL
$6.77 - $14.41 $26,694 - $56,818
-3,943 Reduced 15.74%
21,113 $157,000
Q2 2021

Aug 16, 2021

BUY
$14.52 - $22.46 $363,813 - $562,757
25,056 New
25,056 $364,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $566M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.